2 days ago · The trial, conducted and funded by GenFleet Therapeutics (Shanghai), Inc. (“Genfleet”), was an open-label single-arm multicenter Phase 2a study in China evaluating …

Jun 10, 2024 · A phase 2a study (NCT04588922) evaluating the CDK9 inhibitor SLS009 as treatment for patients with relapsed/refractory acute myeloid leukemia (AML) has completed …

Nov 5, 2024 · We hypothesized that the addition of SLS009, a highly selective CDK9 inhibitor, to Azacitidine/VEN (AZA/VEN) may abrogate resistance to venetoclax and result in clinical …

Oct 16, 2023 · The Phase 2a clinical trial of SLS009 is an open label, single arm, multi-center study that is designed to evaluate safety, tolerability, and efficacy at two dose levels, 45 mg …

May 1, 2024 · The Phase 2a clinical trial of SLS009 is an open-label, single-arm, multi-center study designed to evaluate the safety, tolerability, and efficacy of SLS009 in combination with …

1 day ago · The Company is also developing SLS009 (formerly GFH009) - potentially the first and best-in-class differentiated small molecule CDK9 inhibitor with reduced toxicity and increased …

2 days ago · Summary of Phase 2a data of SLS009 in DLBCL. Patients Characteristics. 9 r/r DLBCL patients were enrolled: 3 with germinal center B-cell like (GCB) and 6 with activated B …

Phase 2a Study of SLS009, a Highly Selective CDK9 Inhibitor, In Combination with Azacitidine and Venetoclax for Relapsed/Refractory Acute Myeloid Leukemia After Prior Venetoclax …

Mar 26, 2024 · Sellas has announced positive topline findings from the phase 2a portion of a phase 1/2 trial (NCT04588922) of SLS009 (formerly GFH009) in patients with …

Mar 27, 2024 · A phase 1/2 trial showed that SLS009 in combination with azacitidine and venetoclax achieved a 50% response rate in relapsed/refractory acute myeloid leukemia.